Key facts
- Notable investors include Symbiotic Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for RNA NanoBiotics
- ·The full record, as it builds
Funding rounds
No funding rounds for RNA NanoBiotics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RNA NanoBiotics
Developer of a nanoparticle-based drug delivery system designed to enable targeted treatment of cancer. The company offers a platform utilizing self-assembling junction structures for precise delivery of chemotherapeutics and RNA-based therapeutics, enabling oncology researchers and clinicians to improve treatment specificity while reducing off-target effects.
- Sector
- Healthcare
- HQ
- Columbus, OH, United States
- Founded
- 2024
- Employees
- 5
- Website
- rna-nano.com/
- Ownership
- Privately Held (backing)
RNA NanoBiotics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RNA NanoBiotics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RNA NanoBiotics in its N-PORT filings yet. We sweep new filings monthly.